Clinical trial
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
NCT00402766 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00402766 |
|---|---|
| Title | Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma |
| Official title | Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Mesothelioma |
| Intervention type | Drug |
| Interventions | Cisplatin, Imatinib Mesylate, Pemetrexed, Dexamethasone |
| Enrollment | 19 |
| Start date | Aug 1, 2006 |
| Primary completion | Feb 1, 2014 |
| Completion | Feb 1, 2014 |
| First posted | Nov 22, 2006 |
| Last update posted | Nov 18, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: